| Literature DB >> 35749072 |
Luciano Gonçalves Fernandes1, Fernando de Azevedo Cruz Seara1.
Abstract
This manuscript aims to provide a simple and concise discussion on heart rate variability (HRV) for small animal veterinarians. Despite the fact that heart rate variability analysis techniques have been used for quite a long time in medical sciences, it seems to be not completely understood by a large fraction of veterinarian professionals, thereby, reducing the possible benefits to patients that could arise from such information. The analysis of the R-R intervals enables the veterinarian to evaluate autonomic sympathetic and parasympathetic modulation of the heart, composing the so-called cardiac autonomic balance. Several pathophysiological states lead to profound changes in autonomic balance, especially in the cardiovascular system. Therefore, heart rate variability methods remain a valuable and powerful tool for the diagnosis and prognosis of cardiovascular diseases. Copyright Fernandes et al.Entities:
Keywords: autonomic nervous system; cardiac interval; heart rate variability; small animals; veterinary cardiology
Year: 2021 PMID: 35749072 PMCID: PMC9179192 DOI: 10.29374/2527-2179.bjvm003621
Source DB: PubMed Journal: Rev Bras Med Vet ISSN: 0100-2430
Figure 1ECG tracing (A) showing consecutives R-R intervals enlisted in a table (B) that in turn is used to plot the interval histogram or density plot (C). Through this graph it is possible to visually inspect the HRV. Most time domain methods are derived from the statistical properties of the time series or from geometrical properties of the density plot.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the SDNN values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 5 min | 58.22?44.46 ms | CKD4: 29.38?22.15 ms |
|
| Canine | 5 min | 61.9 ms (median), 60-77.1 ms (95% CI) | - |
|
| Canine | 3 h | 208.88?77.1 ms | SSS: 208.86?77.1 ms, CMVD: 378.16?40.43 ms |
|
| Canine | 24 h | 331?87 ms | mDCM: 314?56 ms, sDCM: 272?68 ms |
|
| Canine | 24 h | 268?74.6 ms | CME: 83?65 ms |
|
| Canine | 30 min | 143.8 ms (median), 84.8-250.5 ms (range) | ART: 91.2 ms (median), 83.3- 119.4 ms (range); NEO: 193.1 ms (median), 70.9-344.2 ms (range) |
|
| Canine | 14 h | 150.3?10.9 ms | MMVD: 117.8?9 ms |
|
| Canine | 24 h | 293?122 ms | ARVC: 378?73 ms, ARVC-CHF: 152?46 ms |
CI, confidende interval; ms, millisecons.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the SDANN values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 3 h | 70.75?30.9 ms | SSS: 125.5?58.69 ms, CMVD: 54.3?25.7 ms |
|
| Canine | 24 h | 168.3?39.14 ms | CME: 56.05?37.3 ms |
|
| Canine | 14 h | 76.7?12.6 ms | MMVD: 57.6?7.9 ms |
|
| Canine | 24 h | 172?46 ms | ARVC: 176?35 ms, ARVC-CHF: 82?21 ms |
SSS, sick sinus syndrome; CMVD, chronic mitral valve disease; CKD4, chronic kidney disease stage 4; MMVD, myxomatous mitral valve disease; ms, milliseconds; CME, chronic monocytic ehrlichiosis; ARVC, arrhythmogenic right ventricular cardiomyopathy; CHF, chronic heart failure. Data are presented as mean ? standard deviation, unless stated otherwise.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the SDNNidx values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 3 h | 190.75?76.12 ms | SSS: 341.4?56.69 ms, CMVD: 117.21?70.5 ms |
|
| Canine | 24 h | 216.9?74.28 ms | CME: 57.55?55.9 ms |
|
| Canine | 14 h | 128.7?9.4 ms | MMVD: 106.6?10.2 ms |
SSS, sick sinus syndrome; CMVD, chronic mitral valve disease; MMVD, myxomatous mitral valve disease; CME, chronic monocytic ehrlichiosis. Data are presented as mean ? standard deviation, unless stated otherwise
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the RMSSD values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 5 min | 74.05?52.86 ms | CDK4: 40.63?24.77 ms |
|
| Canine | 5 min | 56.6 ms (median), 69.9 - 102.5 ms (95% CI) | - |
|
| Canine | 3 h | 259?120.17 ms | SSS: 54.1?87.55 ms, CMVD: 172.66?116.68 ms |
|
| Canine | 24 h | 325?118 ms | mDCM: 295?72 ms, sDCM: 245?101 ms |
|
| Canine | 24 h | 146.9?45.5 ms | CME: 55.2?50 ms |
|
| Canine | 30 min | 166.8 ms (median), 52.9-198.9 ms (range) | ART: 64.5 ms (median), 58.7-97.2 ms (range); NEO: 277.1 (median), 58.2-414.7 (range) |
|
| Canine | 14 h | 133.1?9.4 ms | MMVD: 112.8?10.3 ms |
SSS, sick sinus syndrome; CMVD, chronic mitral valve disease; CKD4, chronic kidney disease stage 4; MMVD, myxomatous mitral valve disease; ART, arthritis; NEO, neoplasia; CME, chronic monocytic ehrlichiosis; mDCM, mild/moderate dilated cardiomyopathy; sDCM, severe dilated cardiomyopathy; ms, milliseconds; CI, confidence interval. Data are presented as mean ? standard deviation, unless stated otherwise.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the pNN50 values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 5 min | 27.5% (median), 29.2 - 41.7% (95% CI) | - |
|
| Canine | 3 h | 71.84?13.69% | SSS: 86.68?8.12%, CMVD: 51.56?32.5% |
|
| Canine | 24 h | 56?10% | mDCM: 52?9%, sDCM: 48?11% |
|
| Canine | 24 h | 55.87?12.8% | CME: 14.56?20.1% |
|
| Canine | 14 h | 46.9?5.1% | MMVD: 33.6?4.0% |
SSS, sick sinus sydrome; CMVD, chronic mitral valve disease; MMVD, myxomatous mitral valve disease; CI, Confidence Interval; CME, chronic monocytic ehrlichiosis; mDCM, mild/moderate dilated cardiomyopathy; sDCM, severe cardiomyopathy. Data are presented as mean ? standard deviation, unless stated otherwise.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the HTI values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 30 min | 269.9 ms (median); 153.6 - 437.5 ms (range). | ART: 332.1 ms (median), 140.7 - 375.0 ms (range); NEO: 242.2 ms (median), 175.8 - 384.8 ms (range) |
|
| Canine | 24 hours | 267.37?113.38 ms | CME: 648.88?238.97 ms |
ART, arthritis; NEO, neoplasia; CME, chronic monocytic ehrlichiosis; ms, milliseconds. Data are presented as mean ? standard deviation, unless stated otherwise.
Figure 2(A) Lorenz plot of a dog with a good HRV (comet); (B) Lorenz plot of a dog with a poor HRV (disk). It is also possible to observe that artifacts or arrhythmias are clustered in a different region of the graph, making it possible to identify these events; (C) Density histogram of the same dog as seen in A; (D) Density histogram of the same dog as seen in B, where it is possible to observe that arrhythmias or artifacts present different modal frequencies.
Figure 3(A) Representation of an undulatory signal with a frequency of 6.0 Hz; (B) Undulatory signal with a frequency of 1.0 Hz (C) Undulatory signal with a frequency of 0.1 Hz; (D) Signal representing an aperiodic random noise; (E) Summation of the signals presented at panels A, B, C, and D; (F) Graph of power spectrum density decomposing (by FFT algorithm) the signal presented in panel E. Observe the peaks representing each one of the composing frequencies and the aperiodic noise at the baseline.
Figure 4(A) Periodogram of a 15-minute ECG recording, illustrating the HRV over time; (B) Power spectral density graph obtained by FFT from the recording shown in panel A, indicating the areas corresponding to each frequency band. (VLF: 0.003 - 0.04 Hz, LF: 0.04 - 0.15 Hz, HF: 0.15 - 0.4 Hz.)
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the VLF values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Canine | 5 min | 164 ms2 (median), 274 - 618 ms2 (95% CI) | - |
|
| Canine | 3 h | 984.96?327.7 ms2 | |
|
| Canine | 24 h | 14776?8835 ms2 | mDCM: 14363?7957 ms2, sDCM: 11874?4969 ms2 |
|
| Canine | 24 h | 544.5?369.9 ms2 | MMVD: 873.8?755.8 ms2, MMVD+HF: 269.5?278.6 ms2 |
MMVD, myxomatous mitral valve disease; HF, heart failure; ms, milliseconds; CI, Confidence Interval; mDCM, mild/moderate dilated cardiomyopathy; sDCM, severe cardiomyopathy. Data are presented as mean ? standard deviation, unless stated otherwise.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the LF values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Feline | 4 min | Home: 1.37 ms2(mean), 0.31 - 8.6 ms2 (range); Hospital: 1.92 ms2 (mean), 0.36 - 9.89 ms2 (range) | - |
|
| Canine | 5 min | 19.69 ?14.49 n.u. | CDK4: 25.55?16.59 n.u. |
|
| Canine | 5 min | 652 ms2 (median), 714 - 1113 ms2 (95% CI) | - |
|
| Canine | 3 h | 1501.21?736.32 ms2 | |
|
| Canine | 24 h | 21403?20190 ms2 | mDCM: 28879?20109 ms2, sDCM: 18247?11172 ms2 |
|
| Canine | 6 h | 330?150 ms2 | - |
|
| Canine | 20 min | 122.5?46.18 ms2 | oDCM: 90.4? 29.4 ms2, DCM-CHF: 50.0?36.1 ms2 |
|
| Canine | 24 h | 1026.2?788.7 ms2 | MMVD: 1082.5?831.7 ms2, MMVD+HF: 617.5?472.4 ms2 |
|
| Canine | 14 h | 2356.5?197.4 ms2 | MMVD: 2447.7?397.7 ms2 |
MMVD, myxomatous mitral valve disease; DCM-CHF, Dilated cardiomyopathy - congestive heart failure stage; mDCM, mild/moderate dilated cardiomyopathy; sDCM, severe cardiomyopathy; oDCM, occult dilated cardiomyopathy; n.u., normalized units. Data are presented as mean ? standard deviation, unless stated otherwise.
Summary results of selected studies from the literature, depicting the recording length for data acquisition and the HF values for healthy animals or those presenting pathophysiological conditions.
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Feline | 4 min | Home: 2.19 ms2(mean), 0.18 - 31.72 ms2 (range); Hospital: 1.16 ms2 (mean), 0.19 - 10.2 ms2 (range) | - |
|
| Canine | 5 min | 79.52 ?14.08 n.u. | CDK4: 69.75?16.36 n.u. |
|
| Canine | 5 min | 635 ms2 (median), 932 - 2385 ms2 (95% CI) | - |
|
| Canine | 3 h | 5845.45?2914.20 ms2 | |
|
| Canine | 24 h | 61298?37695 ms2 | mDCM: 58800?29147 ms2,sDCM: 43240?26999 ms2 |
|
| Canine | 6 h | 1993?754 ms2 | - |
|
| Canine | 20 min | 2589.1?663.9 ms2 | oDCM: 2205.1? 752.11 ms2, DCM-CHF: 9.68?6.9 ms2 |
|
| Canine | 24 h | 19849.7?29563.5 ms2 | MMVD: 5301?6605 ms2, MMVD+HF: 1972?3669.1 ms2 |
|
| Canine | 14 h | 7204.9?1525.1 ms2 | MMVD: 8243.6?2323.2 ms2 |
CKD4, chronic kidney disease stage 4; MMVD, myxomatous mitral valve disease; DCM-CHF, Dilated cardiomyopathy-congestive heart failure stage; ms, milliseconds; CI, Confidence Interval; mDCM, mild/moderate dilated cardiomyopathy; sDCM, severe cardiomyopathy; oDCM, occult dilated cardiomyopathy; n.u., normalized units. Data are presented as mean ? standard deviation, unless stated otherwise.
Summary results of selected studies from the literature, depicting the study, species, recording length for data acquisition, and the LF:HF ratio values for healthy animals or those presenting pathophysiological conditions (expressed as absolute units).
| Study | Species | Recording length | Healthy | Pathophysiological conditions |
|---|---|---|---|---|
|
| Feline | 4 min | Home: 0.63 (mean), 0.16 - 4.9 (range); Hospital: 1.65 (mean), 0.4 - 6.12 (range) | - |
|
| Canine | 5 min | 0.28?0.25 | CDK4: 0.48?0.32 |
|
| Canine | 5 min | 0.99 (median), 1.07 - 1.68 (95% CI) | - |
|
| Canine | 3 h | 0.25?0.11 | SSS: 0.25?0.11; CMVD: 0.4?0.13 |
|
| Canine | 24 h | 0.38?0.27 | mDCM: 0.11?1.46; sDCM: 0.24?1.38 |
|
| Canine | 6 h | 0.164?0.029 | - |
|
| Canine | 20 min | 0.354?0.156 | oDCM: 0.825?0.519, DCM-CHF: 15.1?5.88 |
|
| Canine | 24 h | 0.39?0.49 | MMVD: 0.85?1.03, MMVD+HF: 1.07?1.23 |
|
| Canine | 14 h | 0.44?0.06 | MMVD: 1.01?0.16 |
SSS, sick sinus syndrome; CKD4, chronic kidney disease stage 4; MMVD, myxomatous mitral valve disease; HF, heart failure; DCM-CHF, Dilated cardiomyopathy-chronic heart failure stage; CI, Confidence Interval; mDCM, mild/moderate dilated cardiomyopathy; sDCM, severe cardiomyopathy; oDCM, occult dilated cardiomyopathy. Data are presented as mean ? standard deviation, unless stated otherwise.